Researchers Develop Improved Extracellular Vesicle Platform for RNA Interference Therapy Delivery
Researchers have developed a modular extracellular vesicle (EV) platform that significantly improves the loading and cytosolic delivery of short hairpin RNA (shRNA) for gene silencing. The platform combines AGO2-assisted RNA loading with fusogen-mediated delivery to overcome two longstanding bottlenecks in EV-based RNA therapeutics. The findings suggest a potential path to delivering RNA interference therapies beyond the liver, including to the brain.
A study posted to bioRxiv describes an engineered extracellular vesicle platform designed to address two core limitations of EV-mediated RNA delivery: inefficient loading of RNA cargo and poor release of that cargo into the cytosol after cellular uptake. By incorporating Argonaute 2 (AGO2)-assisted loading, the researchers achieved up to 3.7 shRNA copies per vesicle and developed a quantitative, molecule-resolved method to assess delivery potency. The engineered EVs demonstrated robust gene silencing at picomolar inhibitory concentrations across multiple cell types in vitro. Critically, the platform also induced significant target gene knockdown in mouse brain tissue following intracerebral administration, a delivery site largely inaccessible to existing RNA therapeutic platforms such as lipid nanoparticles and GalNAc conjugates. The authors argue that coordinating both loading efficiency and cytosolic release engineering is essential to unlocking the broader therapeutic potential of EV-based small RNA delivery.
What's missing
As a preprint, this study has not yet undergone peer review. Key limitations and open questions include: whether intracerebral administration is clinically practical at scale compared to systemic delivery routes; the immunogenicity and off-target effects of the engineered EVs in vivo; long-term durability of gene silencing; and whether the 3.7 copies/EV loading efficiency is sufficient for therapeutic dosing in larger animal models or humans.
What different sources said
- bioRxivCenter
Quantitative Assessment of shRNA Loading and Delivery Efficiency of Engineered Extracellular Vesicles
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.